German drugmaker Stada Arzneimittel reported first-half 2011 results with 7% growth in group sales to €829.7 million euros ($1.18 billion), driven by 5% growth in generics revenues to 572.1 million euros and 14% growth in branded products sales to 231.0 million euros.
EBITDA increased 7% to 153.5 million euros, operating profits grew 9% to 107.6 million euros and net income advanced 12% to 56.1 million euros, or 0.95/share. Adjusted EBITDA grew 8% to 160.2 million euros, adjusted operating profit was up 11% to 121.4 million euros, adjusted net income increased 10% to 65.5 million euros, or 1.11 per share.
For full-year 2011, the company expects adjusted group sales of around 2.15 billion euros, EBITDA of 430 million euros and net income of 215 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze